|
|
Cleveland Clinic 21st Intensive Review of Cardiology
Cleveland Clinic’s acclaimed faculty shares its unparalleled expertise with its 21st Intensive Review of Cardiology. This Board and re-certification resource serves as a forum to critically review current thinking and management of all major cardiovascular disciplines. Focus is placed on the delivery of contemporary medicine, including complex patient management and decision-making for practicing cardiologists. Worth up to 15.75 AMA PRA Category I Credits™, this enduring material is also... |
|
|
Monitor Patients with Carpal Tunnel Syndrome and Catch Transthyretin Cardiomyopathy Early in the Course
Target Audience
Healthcare providers in internal medicine, family medicine, surgery, cardiology, neurology, and healthcare professionals caring for patients with carpal tunnel syndrome and/or heart failure.
Program Overview
ATTR is a type of amyloidosis that affects the heart as well as other tissues such as the synovium of carpal tunnel. Bilateral carpal tunnel syndrome proceeds the symptoms of ATTR cardiomyopathy by a number of years. Topics on when to refer patients with carpal tunnel ... |
|
|
Update in Clinical Cardiology - LIVE STREAMING or IN PERSON
The Comprehensive Clinical Cardiology Update
Evaluation • Treatment • Patient Care • Procedures • Challenging Cases
Update in Clinical Cardiology will be held on October 16 " 18, 2024. You have the option to attend either online as the course is live streamed or in person in Boston, MA.
OVERVIEW
This course provides comprehensive updates for state-of-the-art care and guidance to incorporate them into daily practice to optimize patient outcomes.
Coverage includes:
• ... |
|
|
Raising the Bar in ATTR Amyloidosis A Training Set on Diagnosis and Treatment
There is considerable heterogeneity in the clinical manifestations of ATTR amyloidosis, which are often dependent on both genetic and environmental factors. Once a fatal diagnosis with no effective therapies available, research in ATTR amyloidosis is rapidly evolving and new pharmacotherapies that demonstrate improved quality of life and life expectancy for patients have been developed. Despite this progress, treatment options remain limited, underscoring the need to continue to expand the tre... |
|
|
Overcoming Challenges to Recognizing, Diagnosing, and Managing Transthyretin Amyloid Cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM), once considered rare, is more prevalent than previously thought. Diagnosing this condition can be a challenge, as early symptoms may be nonspecific and attributable to aging, whereas later more severe symptoms can be mistaken for other cardiovascular conditions such as heart failure or may be confused with other causes of amyloidosis. This can be particularly problematic, as it can delay appropriate treatment.
Advances in noninvasive methods f... |
|